CN108912007B - 一种右氯谷胺的制备方法 - Google Patents
一种右氯谷胺的制备方法 Download PDFInfo
- Publication number
- CN108912007B CN108912007B CN201810635961.8A CN201810635961A CN108912007B CN 108912007 B CN108912007 B CN 108912007B CN 201810635961 A CN201810635961 A CN 201810635961A CN 108912007 B CN108912007 B CN 108912007B
- Authority
- CN
- China
- Prior art keywords
- preparation
- reaction
- tert
- dextrochloroglutamine
- binding agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- AJDUMMXHVCMISJ-CYBMUJFWSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxo-5-phenylmethoxypentanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(O)=O)CCC(=O)OCC1=CC=CC=C1 AJDUMMXHVCMISJ-CYBMUJFWSA-N 0.000 claims abstract description 9
- VTXNOVCTHUBABW-UHFFFAOYSA-N 3,4-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C(Cl)=C1 VTXNOVCTHUBABW-UHFFFAOYSA-N 0.000 claims abstract description 6
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims abstract description 5
- 150000008065 acid anhydrides Chemical class 0.000 claims abstract 3
- 238000006243 chemical reaction Methods 0.000 claims description 23
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical group CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 8
- -1 amide compound Chemical class 0.000 claims description 7
- 239000011230 binding agent Substances 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical group CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims description 3
- 238000006555 catalytic reaction Methods 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 229940100684 pentylamine Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 9
- ZAAUEOJGRAIXHU-UHFFFAOYSA-N n-(3-methoxypropyl)pentan-1-amine Chemical compound CCCCCNCCCOC ZAAUEOJGRAIXHU-UHFFFAOYSA-N 0.000 abstract description 4
- 230000010933 acylation Effects 0.000 abstract 1
- 238000005917 acylation reaction Methods 0.000 abstract 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- 101800001982 Cholecystokinin Proteins 0.000 description 7
- 102100025841 Cholecystokinin Human genes 0.000 description 7
- 229940107137 cholecystokinin Drugs 0.000 description 7
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 2
- 229930182847 D-glutamic acid Natural products 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- BGGHCRNCRWQABU-SNVBAGLBSA-N (2r)-2-azaniumyl-5-oxo-5-phenylmethoxypentanoate Chemical compound [O-]C(=O)[C@H]([NH3+])CCC(=O)OCC1=CC=CC=C1 BGGHCRNCRWQABU-SNVBAGLBSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000946808 Xenopus laevis Cholecystokinin A Proteins 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/14—Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
技术领域
本发明属于医药领域,具体涉及一种右氯谷胺的制备方法。
背景技术
胆囊收缩素(cholecystokinin,CCK)是广泛存在于胃肠内的重要肽类激素,主要调节胆囊收缩和胰腺酶的分泌。CCK的生物作用由I型胆囊收缩素(cholecystokinin type-1,CCK1)和II型胆囊收缩素(cholecystokinin type-2,CCK2)两种受体亚型与靶器官结合而介导。其中CCK1调节胃肠道功能,CCK2则主要存在于中枢神经系。右氯谷胺(Dexloxiglumide,分子结构如式1所示)是为一强效及选择性CCK1受体拮抗剂,主要用于治疗便秘型肠易激综合征,是临床胃肠病学研究最前沿的CCK1受体拮抗剂。
式1.右氯谷胺的分子结构式
目前,有关右氯谷胺的合成制备方法的文献并不多,主要有专利US5391574和US5602179,以及文献文献《J.Med.Chem.》Vol.35,(1992,28-38),这三篇文献内容几乎相同(见反应路线1),均报道了从化合物2开始合成目标产物1及其类似化合物的制备方法。
反应路线1
除此之外,从SciFinder数据库中也有一篇报道右氯谷胺合成的文献(见反应路线2)。该方法以D-谷氨酸为起始原料,经两步反应先合成中间体2,除最后一步合成1的方法与上述3篇文献不同之外,其余均相似。
反应路线2
概况起来,以上方法的主要缺点如下:
1.反应总收率极低,以D-谷氨酸为原料合成右氯谷胺1,总收率约10%左右。
2.在合成1时,由于中间体4有个未保护的羧基,与原料3,4-二氯苯甲酰氯反应生成酯,反应后需要用二环已基胺成盐纯化,然后再酸化成目标产物1,使得这一步后处理不仅繁琐,而且收率仅为63.8%。
发明内容
本发明的目的在于根据上述背景技术的现状,提供了一种操作简单、收率高的右氯谷胺的制备方法。
为了解决上述技术问题,本发明提供了如下的技术方案:
一种右氯谷胺的制备方法,包括:
(2)脱去步骤(1)所述的酰胺化合物的叔丁氧羰基,得到
进一步,步骤(1)所述混合酸酐法的过程包括:
在缚酸剂的存在下,N-叔丁氧羰基-D-谷氨酸-5-苄酯与氯甲酸酯反应生成混合酸酐,所得的混合酸酐再与N-(3-甲氧基丙基)-戊胺反应,得到所述的酰胺化合物:上述反应较为剧烈,优选在-5~-20℃下进行。N-叔丁氧羰基-D-谷氨酸-5-苄酯、氯甲酸酯和N-(3-甲氧基丙基)-戊胺的摩尔用量可控制在1:1:1左右。
优选地,所述缚酸剂为N-甲基吗啉,所述氯甲酸酯为氯甲酸异丁酯。
进一步,在有机溶剂中,步骤(1)所述的酰胺化合物与HCl反应,脱去叔丁氧羰基,优选地,所述有机溶剂为乙酸乙酯。优选地,HCl的浓度为2~3mol/L。
脱叔丁氧羰基保护在室温下进行即可。反应完成后,体系加水稀释,调pH至9~10后,分液,所得有机相再经饱和NaCl洗涤、无水Na2SO4干燥,得到
优选地,所述缚酸剂为碳酸钠。
本发明的有益效果
1.每步收率均较高(均可达80%以上),从而提高右氯谷胺1的总收率。
2.最后一步脱苄基保护后,所获得的目标产物1不仅较纯,而且收率较高,可直接用丙酮和水的混合溶剂重结晶,操作更简便。
具体实施方式
以下对本发明的优选实施例进行说明,应当理解,此处所描述的优选实施例仅用于说明和解释本发明,并不用于限定本发明。
部分化学术语可采用以下缩写符号表示:
乙基:Et;甲基:Me;乙酰基:Ac;苄氧羰基:Cbz;叔丁氧羰基:Boc;
三乙胺:TEA;四氢呋喃:THF;N,N-二甲基甲酰胺:DMF;N-甲基吗啉:NMM;
mol/L:M。
本发明右氯谷胺的反应路线如下:
实施例1.制备N-Boc-D-谷氨酸-5-苄酯(化合物6)
250mL的烧瓶中加入4.84g(0.02mol,98%)的D-谷氨酸5-苄酯(化合物5)、60mL的四氢呋喃和20mL的N,N-二甲基甲酰胺混合溶液,8.1g的三乙胺和6.55g的二碳酸二叔丁酯。加热至60℃反应4h后,减压蒸干四氢呋喃和N,N-二甲基甲酰胺,获得的油状物在冰浴条件下用100mL,浓度为0.25M的KHSO4溶液酸化至pH至2.0-3.0,搅拌15min。乙酸乙酯(30mL)萃取4次。干燥,减压蒸干溶剂,获得的油状液体直接用于下一步的反应,收率91%。IR(KBr):3421,2977,2930,1718,1508,1457,1393,1368,1251,1165,1054,750,698cm-1;1H NMR(400MHz,CDCl3)δ7.23(d,J=4.6Hz,5H),5.00(s,2H),4.19(s,1H),4.12(s,1H),2.38(d,J=7.0Hz,3H),2.16-2.09(m,3H),1.32(s,10H).13C NMR(101MHz,CDCl3)δ176.42,173.14,155.91,135.77,128.56,128.35,128.25,80.09,66.52,53.32,30.39,30.11,28.33,27.52,18.01.
实施例2.制备化合物7
100mL的瓶中加入6.9g的N-Boc-D-谷氨酸-5-苄酯(化合物6),溶于50mL的四氢呋喃中,搅拌冷却至-10℃,加入2.02g的N-甲基吗啉,剧烈搅拌的同时再滴加2.73g的氯甲酸异丁酯(10min内加完)。于-10℃搅拌反应20min后,分三批加入3.25g的N-(3-甲氧基丙基)-戊胺该温度下反应5h。减压蒸干滤液,获得的残渣加入60mL的乙酸乙酯,先后用0.5M的盐酸(2×30mL)、1M碳酸氢钠(2×20mL)和饱和NaCl(2×20mL)分别萃取。无水Na2SO4干燥,蒸干溶剂,获得的粘稠状淡黄色液体中加入50mL浓度为2.4M的HCl乙酸乙酯溶液,室温反应1h。反应后,反应体系中加入20mL的水稀释。在冰浴的条件下用15-20mL浓度为5M的NaOH调pH至9-10,搅拌15min后分液。有机相再用15mL饱和NaCl洗2次,分离两相,有机相用无水Na2SO4干燥,蒸干,获得6.76g淡黄色油状液体(即化合物7),收率92%。IR(KBr):3421,2958,2931,2872,1736,1711,1642,1497,1456,1389,1366,1249,1170,1119,1051,750,698cm-1;1H NMR(400MHz,CDCl3)δ7.25(d,J=4.6Hz,5H),5.05(s,2H),4.41(dt,J=30.9,6.3Hz,1H),3.46(ddd,J=30.1,14.6,7.4Hz,2H),3.34(dd,J=20.0,6.8Hz,2H),3.33-3.15(m,4H),3.19-3.09(m,1H),3.13-2.99(m,1H),2.47-2.32(m,1H),2.28-2.22(m,2H),2.01(dd,J=11.0,5.2Hz,1H),1.44(s,2H),1.22(ddt,J=23.0,13.7,5.6Hz,5H).13CNMR(101MHz,CDCl3)δ177.35,170.33,134.95,127.53,127.15,125.88,69.25,67.70,65.22,57.56,52.69,46.56,42.94,29.14,28.08,26.02,24.57,21.40,12.95.
实施例3.制备化合物8
将7.56g的化合物7置于250mL的烧瓶中,加入40mL浓度为0.5M的Na2CO3和20mL的四氢呋喃。溶解后,于0-5℃滴加20mL含有3.89g 3,4-二氯苯甲酰氯的THF溶液(滴加超过30min),并在此温度下继续反应1h。反应结束后蒸干四氢呋喃,获得的水相用60mL的二氯甲烷稀释,过滤除去不溶性杂质,滤液分离两相。有机相依次用20mL1M的NaHCO3、1M的盐酸和饱和的NaCl水溶液分别萃取2次,蒸干溶剂,获得9.71g淡黄色的油状液体(即化合物8),收率为89%。IR(KBr):3422,2960,2931,2873,1735,1711,1642,1610,1497,1455,1387,1366,1250,1172,1118,1050,778,750,698cm-1;1H NMR(400MHz,CDCl3)δ7.90(m,1H),7.70(m,1H),7.46(m,1H),7.25(d,J=4.6Hz,5H),7.20(s,1H),5.05(s,1H),4.41(dt,J=30.9,6.3Hz,1H),3.46(ddd,J=30.1,14.6,7.4Hz,2H),3.34(dd,J=20.0,6.8Hz,2H),3.33-3.15(m,4H),3.19-3.09(m,1H),3.13-2.99(m,1H),2.47-2.32(m,1H),2.28-2.22(m,2H),2.01(dd,J=11.0,5.2Hz,1H),1.44(s,2H),1.22(ddt,J=23.0,13.7,5.6Hz,5H).13C NMR(101MHz,CDCl3)δ176.32,170.92,164.22,134.99,134.91,132.30,131.76,129.37,128.55,127.54,127.19,125.82,125.65,69.16,67.95,57.54,47.77,43.27,28.59,27.94,27.80,26.66,26.18,21.43,12.98.
实施例4.制备右氯谷胺(化合物1)
250mL的瓶中加入11.03g的化合物8,加入150mL的甲醇,溶解后,在N2保护的条件下加入1g 10%的钯碳,在室温下通入H2(压力为3-5bar)反应3h。反应结束后过滤除去钯碳,减压蒸干甲醇,所得残渣用水和乙醇的混合溶液(2:1,v/v)重结晶,获得7.65g右氯谷胺,收率为85%。IR(KBr):3449,2961,2930,2868,1699,1645,1456,1431,1380,1265,1206,1117,738,700cm-1;1H NMR(400MHz,CDCl3)δ10.61(s,1H),8.04(s,1H),7.92-7.82(m,1H),7.68(m,1H),7.47(m,1H),7.20(s,1H),5.14(s,1H),3.69-3.41(m,2H),3.39-3.19(m,6H),3.19-2.97(m,1H),2.43(s,2H),2.13-1.98(m,1H),1.97-1.79(m,2H),1.74(s,1H),1.58(dd,J=14.4,5.5Hz,1H),1.46(s,1H),1.39-1.11(m,5H),0.79(t,J=6.3Hz,3H).13C NMR(101MHz,CDCl3)δ175.61,170.92,164.22,134.99,132.30,131.76,129.37,128.55,125.65,69.06,68.25,57.54,47.89,43.31,28.68,28.00,27.84,26.67,26.09,21.33,12.93.
最后应说明的是:以上所述仅为本发明的优选实施例而已,并不用于限制本发明,尽管参照前述实施例对本发明进行了详细的说明,对于本领域的技术人员来说,其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (4)
2.根据权利要求1所述的制备方法,其特征在于:步骤(1)中,所述缚酸剂为N-甲基吗啉,所述氯甲酸酯为氯甲酸异丁酯。
3.根据权利要求1所述的制备方法,其特征在于:步骤(2)中,所述有机溶剂为乙酸乙酯。
4.根据权利要求1所述的制备方法,其特征在于:步骤(3)中,所述缚酸剂为碳酸钠。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810635961.8A CN108912007B (zh) | 2018-06-20 | 2018-06-20 | 一种右氯谷胺的制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810635961.8A CN108912007B (zh) | 2018-06-20 | 2018-06-20 | 一种右氯谷胺的制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108912007A CN108912007A (zh) | 2018-11-30 |
| CN108912007B true CN108912007B (zh) | 2021-02-26 |
Family
ID=64421171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810635961.8A Active CN108912007B (zh) | 2018-06-20 | 2018-06-20 | 一种右氯谷胺的制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108912007B (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988005774A1 (en) * | 1987-02-05 | 1988-08-11 | Rotta Research Laboratorium S.P.A. | Derivatives of (r) 5-pentylamino-5-oxopentanoic acid with anticholecystokinin activity |
| US4769389A (en) * | 1985-12-17 | 1988-09-06 | Rotta Research Laboratories, S.P.A. | Oxygenated-alkyl derivatives of glutamic and aspartic acids with antagonistic activity to bio-active polypeptides and a method for their preparation |
| US4791215A (en) * | 1984-06-25 | 1988-12-13 | Rotta Research Laboratorium S.P.A. | Derivatives of glutamic acid and aspartic acid |
-
2018
- 2018-06-20 CN CN201810635961.8A patent/CN108912007B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4791215A (en) * | 1984-06-25 | 1988-12-13 | Rotta Research Laboratorium S.P.A. | Derivatives of glutamic acid and aspartic acid |
| US4769389A (en) * | 1985-12-17 | 1988-09-06 | Rotta Research Laboratories, S.P.A. | Oxygenated-alkyl derivatives of glutamic and aspartic acids with antagonistic activity to bio-active polypeptides and a method for their preparation |
| WO1988005774A1 (en) * | 1987-02-05 | 1988-08-11 | Rotta Research Laboratorium S.P.A. | Derivatives of (r) 5-pentylamino-5-oxopentanoic acid with anticholecystokinin activity |
Non-Patent Citations (3)
| Title |
|---|
| Hybrid cholecystokinin (CCK) antagonists: new implications in the design and modification of CCK antagonists;Kerwin, James F.等;《Journal of Medicinal Chemistry》;19890401;第32卷(第4期);第740页左栏第2段和第741页表1 * |
| Structure-Antigastrin Activity Relationships of New (R)-4-Benzamido-5-oxopentanoic Acid Derivatives;Francesco Makovec 等;《J.Med.Chem.》;19920101;第35卷(第1期);第28-38页 * |
| 氯谷胺的合成;孙晋瑞 等;《食品与药品》;20130920;第15卷(第5期);第317-319页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108912007A (zh) | 2018-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106146359B (zh) | α‑酰氧基烯酰胺类化合物温和高效的制备方法及其在酰胺和多肽合成中的应用 | |
| CN106459150B (zh) | 合成五肽的制造方法 | |
| CN111253287A (zh) | 液相汇聚式合成索马鲁肽侧链的方法 | |
| CN111606827B (zh) | 一种制备依度沙班手性胺中间体的方法 | |
| CN103724258B (zh) | 一种索拉非尼的制备方法 | |
| JP2023007949A (ja) | Fmоc基を除去する方法 | |
| CN114478690B (zh) | 一种6,6-二甲基-3-氮杂双环[3.1.0]己烷衍生物的制备方法 | |
| CN108912007B (zh) | 一种右氯谷胺的制备方法 | |
| SU963463A3 (ru) | Способ получени трипептидамидов | |
| CN111072660B (zh) | 一种瑞来巴坦的简便制备方法 | |
| CN110204505B (zh) | (s)-3-苄氧羰基-4-异丙基-2,5-恶唑烷二酮的制备工艺 | |
| CN113667006A (zh) | 一种索马鲁肽二肽侧链的制备方法 | |
| CN113667007A (zh) | 一种索马鲁肽侧链的液相制备方法 | |
| CA2980071A1 (en) | Method for preparation of (4s)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile | |
| CN111100118A (zh) | 一种立他司特杂质及其制备方法 | |
| CN109988121B (zh) | 一种阿考替胺衍生物的制备方法 | |
| CN119638592A (zh) | 一种索玛鲁肽侧链的制备方法 | |
| CN111333505A (zh) | 制备长链脂肪二酸单苄酯的方法及其应用 | |
| CN114621312B (zh) | 一种寡肽烷基侧链的选择性修饰方法 | |
| CN112225708B (zh) | 一种莫沙必利中间体的制备方法 | |
| JP2025532276A (ja) | 非保護アミノ酸をアミノ成分としてアミド及び/又はポリペプチドを合成する方法 | |
| CN112920053B (zh) | 一种手性α-甲基芳乙胺的制备方法 | |
| CN102212034B (zh) | 替米沙坦杂质b的制备方法 | |
| CN117343006B (zh) | 一种arb-272572的制备方法 | |
| CN116082193B (zh) | 一种甲硫酸新斯的明的制备和纯化方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |